European heart journal
-
European heart journal · Dec 2015
Randomized Controlled Trial Multicenter Study Comparative StudyA randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan.
Theoretically, bioresorbable vascular scaffolds (BVSs) may provide superior long-term results compared with permanent metallic drug-eluting stents (DESs). However, whether BVSs are as safe and effective as metallic DESs prior to complete bioresorption is unknown. ⋯ ClinicalTrials.gov, number NCT01844284.
-
European heart journal · Dec 2015
Randomized Controlled Trial Multicenter StudyThe ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
Therapeutic decisions in atrial fibrillation (AF) are often influenced by assessment of bleeding risk. However, existing bleeding risk scores have limitations. ⋯ The five-element ORBIT bleeding risk score had better ability to predict major bleeding in AF patients when compared with HAS-BLED and ATRIA risk scores. The ORBIT risk score can provide a simple, easily remembered tool to support clinical decision making.
-
European heart journal · Dec 2015
Randomized Controlled Trial Multicenter StudyImpact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.
The influence of reticulated platelets (RPs) on platelet inhibition by ticagrelor when compared with prasugrel is unknown. We aimed to determine the influence of RPs on adenosine diphosphate- (ADP-) induced platelet aggregation in patients with acute coronary syndrome who were randomly assigned to receive either ticagrelor or prasugrel for P2Y12 receptor inhibition. ⋯ Reticulated platelets show a greater impact on platelet reactivity in response to prasugrel when compared with ticagrelor.
-
European heart journal · Oct 2015
Multicenter StudyEarly performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study.
Permanent cardiac pacing is the only effective treatment for symptomatic bradycardia, but complications associated with conventional transvenous pacing systems are commonly related to the pacing lead and pocket. We describe the early performance of a novel self-contained miniaturized pacemaker. ⋯ ClinicalTrials.gov ID NCT02004873.
-
European heart journal · Aug 2015
Randomized Controlled Trial Multicenter Study Comparative StudyMarfan Sartan: a randomized, double-blind, placebo-controlled trial.
To evaluate the benefit of adding Losartan to baseline therapy in patients with Marfan syndrome (MFS). ⋯ Losartan was able to decrease blood pressure in patients with MFS but not to limit aortic dilatation during a 3-year period in patients >10 years old. β-Blocker therapy alone should therefore remain the standard first line therapy in these patients.